<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04603001</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-IDH-20001</org_study_id>
    <secondary_id>2020-002830-33</secondary_id>
    <secondary_id>I9Y-OX-JDHB</secondary_id>
    <nct_id>NCT04603001</nct_id>
  </id_info>
  <brief_title>Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations</brief_title>
  <official_title>A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH&#xD;
      inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who&#xD;
      have received standard therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 2 parts: dose escalation and dose expansion. The dose escalation will&#xD;
      enroll eligible patients with select IDH-mutant advanced hematologic malignancies. Once the&#xD;
      maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of LY3410738 is&#xD;
      established, the dose expansion will begin and enroll into 4 cohorts to further evaluate&#xD;
      safety and clinical activity&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Escalation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the activity of LY3410738 as measured by the overall response rate (ORR) per the investigator assessment</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating adverse events and treatment emergent adverse events</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of LY3410738 as measured by the overall response rate (ORR) per investigator assessment</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Escalation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of LY3410738 as measured by Best Overall Response per investigator assessment</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of LY3410738 by Complete Response Rate plus partial hematologic recovery (AML patients)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of LY3410738 by Duration of Response</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the activity of LY3410738 by Hematologic improvement in patients with MDS</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the safety profile and tolerability of LY3410738 including acute and chronic toxicities by collecting and evaluating Adverse events and treatment emergent adverse events</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) properties of LY3410738 by collecting and evaluating serum at protocol specified time points</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacodynamic properties of LY3410738 as expressed by change in 2-HG oncometabolite levels in plasma.</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>For Dose Expansion</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <condition>Myeloproliferative Neoplasms (MPNs)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Arm A (Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients not requiring a strong CYP3A4 inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Escalation Arm B (Monotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients requiring a strong CYP3A4 inhibitor for active management or prevention of a lifethreatening condition, such as an azole administered to prevent invasive fungal infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R AML harboring an IDH1 R132 mutation who have received a prior IDH inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R AML harboring an IDH1 R132 mutation who have not received a prior IDH inhibitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R MDS, chronic myelomonocytic leukemia (CMML) or other advanced hematologic malignancy harboring an IDH1 R132 mutation,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with R/R AML, MDS, CMML or other advanced hematologic malignancy harboring IDH2 mutations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3410738</intervention_name>
    <description>Oral LY3410738</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Dose Escalation Arm A (Monotherapy)</arm_group_label>
    <arm_group_label>Dose Escalation Arm B (Monotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced IDH mutant hematologic malignancy&#xD;
&#xD;
          -  Patients must have received prior therapy&#xD;
&#xD;
          -  Blasts at least 5% in bone marrow.&#xD;
&#xD;
          -  Patients must have a qualifying IDH1 R132, IDH2 R140 or IDH2 R172 mutation&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Ability to swallow capsules or tablets&#xD;
&#xD;
          -  Ability to comply with outpatient treatment, laboratory monitoring, and required&#xD;
             clinic visits for the duration of study participation&#xD;
&#xD;
          -  Willingness of men and women of reproductive potential to observe conventional and&#xD;
             effective birth control for the duration of treatment and for 3 months following the&#xD;
             last dose of study treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Investigational agent or anticancer therapy within 2 weeks or 5 half-lives, whichever&#xD;
             is shorter; or investigational monoclonal antibody within 4 weeks prior to planned&#xD;
             start of LY3410738&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to planned start of LY3410738.&#xD;
&#xD;
          -  Active, uncontrolled clinically significant systemic bacterial, viral, fungal or&#xD;
             parasitic infection or an unexplained fever &gt; 38.5ºC during screening or on the first&#xD;
             day of study drug administration.&#xD;
&#xD;
          -  Another concurrent malignancy requiring active therapy.&#xD;
&#xD;
          -  Active central nervous system involvement&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy greater than CTCAE v5.0 Grade 2 at the&#xD;
             time of starting study treatment except for alopecia.&#xD;
&#xD;
          -  History of hematopoietic stem cell transplant (HSCT) or CAR-T therapy within 60 days&#xD;
             of the first dose of LY3410738&#xD;
&#xD;
          -  Clinically significant cardiovascular disease&#xD;
&#xD;
          -  Active hepatitis B virus (HBV)&#xD;
&#xD;
          -  Active hepatitis C virus (HCV)&#xD;
&#xD;
          -  Clinically significant active malabsorption syndrome or other condition likely to&#xD;
             affect gastrointestinal (GI) absorption of the study drug&#xD;
&#xD;
          -  Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or&#xD;
             inducers and/or P-gp inhibitor, with the exception of patients being treated with&#xD;
             allowed antifungal inhibitors of CYP3A4&#xD;
&#xD;
          -  Treatment with proton pump inhibitor (PPIs) within 7 days of starting LY3410738&#xD;
&#xD;
          -  Any serious underlying medical or psychiatric condition (e.g. alcohol or drug abuse),&#xD;
             dementia or altered mental status or any issue that would impair the ability of the&#xD;
             patient to understand informed consent or that in the opinion of the investigator&#xD;
             would contraindicate the patient's participation in the study or confound the results&#xD;
             of the study&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV), excluded due to potential drug-drug&#xD;
             interactions between anti-retroviral medications and LY3410738&#xD;
&#xD;
          -  Pregnancy, lactation or plan to breastfeeding during the study or within 90 days of&#xD;
             the last dose of study intervention&#xD;
&#xD;
          -  Known hypersensitivity to any of the components of LY3410738 or its formulation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Olek, DO, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>833-LOXO-IDH</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California, Davis - Health Systems</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Limited</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Haut Leveque</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hanover</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>6351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National University Cancer Institute</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinico Y Provincial Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung City</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 12, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loxo</keyword>
  <keyword>LY3410738</keyword>
  <keyword>isocitrate dehydrogenase</keyword>
  <keyword>IDH</keyword>
  <keyword>IDH1</keyword>
  <keyword>IDH2</keyword>
  <keyword>R132</keyword>
  <keyword>R140</keyword>
  <keyword>R172</keyword>
  <keyword>2-hydroxyglutarate</keyword>
  <keyword>2-HG</keyword>
  <keyword>Advanced Hematologic Malignancies</keyword>
  <keyword>Blasts</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>Relapsed/refractory AML</keyword>
  <keyword>R/R AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Chronic Myelomonocytic Leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>Myeloproliferative Neoplasms</keyword>
  <keyword>MPN</keyword>
  <keyword>Advanced Hematologic Cancers</keyword>
  <keyword>Ivosidenib</keyword>
  <keyword>AG-120</keyword>
  <keyword>Vorasidenib</keyword>
  <keyword>AG-881</keyword>
  <keyword>Olutasidenib</keyword>
  <keyword>FT-2102</keyword>
  <keyword>BAY1436032</keyword>
  <keyword>DS-1001</keyword>
  <keyword>IDH-305</keyword>
  <keyword>Enasidenib</keyword>
  <keyword>AG-221</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

